Neutrophil-like cell membrane-coated molybdenum-based nanoclusters for reduced oxidative stress and enhanced neurological recovery after intracerebral hemorrhage.

Excessive reactive oxygen species (ROS) are detrimental to the brain that can result in neurological impairment and inhibiting neurological functionals recovery after intracerebral hemorrhage (ICH). However, there is still a lack of effective treatment for ICH, either with medicine or neurosurgery. Nanozymes with excellent superoxide dismutase and catalase properties can scavenge ROS and may provide therapeutic opportunities for ICH patients. However, the ability of nanozymes to non-invasively target cerebral hemorrhage lesions and further antioxidation effect are still unknown. Herein, neutrophile membrane-disguised molybdenum-based polyoxometalate nanozymes (POM@Mem) were developed to alleviate oxidative stress after ICH. Coating with neutrophil membrane allowed POM to target the hemorrhage sites and further inhibit ROS generation. POM@Mem can improve neuroinflammatory microenvironment and promote behavioral improvement of ICH mouse. Combining neutrophile membrane and nanozymes for targeting brain hemorrhage sites provides an effective strategy for the treatment of ICH. STATEMENT OF SIGNIFICANCE: Excessive reactive oxygen species (ROS) are detrimental to the brain and can lead to neurological impairment, hindering the recovery of neurological functions after intracerebral hemorrhage (ICH). Despite this, effective treatments for ICH, whether pharmaceuticals or neurosurgery, remain scarce. In this study, we developed neutrophil membrane-disguised molybdenum-based polyoxometalate nanozymes (POM@Mem) as a novel approach to alleviate oxidative stress following ICH. The neutrophil membrane coating enabled the POM nanozymes to specifically target hemorrhagic sites, thereby inhibiting ROS production. Additionally, POM@Mem improved the neuroinflammatory microenvironment and facilitated behavioral recovery in ICH mice. The combination of neutrophil membranes and nanozymes for targeted delivery to brain hemorrhage sites offers a promising strategy for the treatment of ICH.